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Commen t a r y
Monoaminergic hypothesis of depression
The monoaminergic hypothesis of depression posits that 
this illness results from a deficit in serotonin (5-HT), 
noradrenaline, and dopamine signaling in the brain. Of 
these monoamines, the serotonergic system has been the 
one most strongly implicated in the pathophysiology 
and treatment of mood disorders. Although this rela-
tionship has not been proven, many findings indirectly 
support this hypothesis: (a) a subgroup of depressed pa-
tients have a very marked reduction of the concentra-
tion of 5-HT in plasma (Sarrias et al., 1987) and of its 
metabolite, 5-hydroxyindoleacetic acid, in the cerebro-
spinal fluid (Asberg et al., 1976) that may reflect de-
creased serotonergic transmission in the brain; (b) most 
prescribed antidepressant drugs increase serotonergic 
transmission in the long term; (c) a clinical study showed 
that in 50% of depressed patients that responded to se-
lective 5-HT reuptake inhibitors (SSRIs) (see Fig. 1), de-
pressive symptoms relapsed after depletion of the 5-HT 
precursor tryptophan (Delgado et al., 1999); (d) recent 
preclinical investigations have reported that an intact 
serotonergic system is required for an antidepressant 
response to experimental treatments such as deep brain 
stimulation or ketamine (Hamani et al., 2010; Gigliucci 
et al., 2013); and (e) optogenetic activation of the pre-
frontal cortex projection to the dorsal raphe (DR) nu-
cleus produces antidepressant-like effects in rodents 
(Covington et al., 2010; Warden et al., 2012). Therefore, 
there is evidence that deficits in serotonergic transmis-
sion are associated with at least some depressive states 
and a poor response to antidepressant drugs (Sachs 
et al., 2015), whereas the activation of 5-HT neurons in 
the DR evokes an antidepressant response.
Role of raphe 5-HT in the effects of antidepressant drugs
Most serotonergic neurons originate in the DR nucleus 
found in the brainstem. This nucleus is highly enriched 
in 5-HT transporters (SERTs) and in inhibitory 5-HT1A 
autoreceptors. Although the roles of extracellular 5-HT 
and 5-HT1A autoreceptors in the DR have been studied 
extensively (Piñeyro and Blier, 1999; Adell et al., 2002), 
their exact function remains unclear. Some studies have 
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shown that 5-HT1A autoreceptors function as sensors 
that respond only when the concentration of endoge-
nous 5-HT in the extracellular compartment becomes 
excessive (Adell et al., 2002), whereas other work has 
provided evidence for tonic activation of 5-HT1A autore-
ceptors under certain experimental conditions (Haddjeri 
et al., 2004). It was first demonstrated in the early 90s 
that current antidepressant drugs predominantly in-
crease extracellular 5-HT in the raphe region (Adell and 
Artigas, 1991; Invernizzi et al., 1992), thereby activating 
inhibitory 5-HT1A autoreceptors, reducing cell firing, 
and having a negative feedback influence on 5-HT re-
lease. Thus, it is likely that the rapid pharmacological 
action of SSRIs (and other antidepressant drugs) in the 
DR—desired to act like an accelerator—initially act as 
a brake in the therapeutic process.
Several recent studies support this contention. Thus, 
the selective knockdown of presynaptic 5-HT1A (auto-
receptors) but not postsynaptic 5-HT1A receptors by 
small-interfering RNA (siRNA) results in clear-cut anti-
depressant-like behaviors in mice (Bortolozzi et al., 
2012). In contrast, mice that overexpress the DR 5-HT1A 
receptor exhibit increased behavioral despair, and no 
behavioral response to antidepressant drugs (Richardson-
Jones et al., 2010). This is consistent with clinical data 
showing that people with increased density or activity of 
5-HT1A autoreceptors are more susceptible to mood dis-
orders and respond poorly to antidepressant treatments 
(Stockmeier et al., 1998; Neff et al., 2009). It is thus evi-
dent that the serotonergic transmission in projection 
areas is controlled, at least in part, by basal serotonergic 
activity on somatodendritic 5-HT1A autoreceptors on 
serotonergic neurons in the raphe (Sharp et al., 1989; 
Riad et al., 2000; Crespi, 2009). Importantly, it is of note 
that there is a substantial delay in the therapeutic effect 
of SSRIs, and it has been subsequently postulated that 
autoinhibitory control caused by increased extracellular 
raphe 5-HT might be responsible for this delay (Artigas 
et al., 1996). Therefore, it is critical to identify the release 
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plasma membrane. These results contrast with those of 
Colgan et al. (2012), who observed action potential–inde-
pendent, but vesicle-dependent release of 5-HT from den-
drites. Further research is needed to determine whether 
the cytoplasmic 5-HT identified by Mlinar et al. (2015) 
represents a “functional” transmitter pool in the DR, i.e., 
if it has physiological and behavioral consequences.
Notably, Mlinar et al. (2015) performed their analyses 
in slices of brainstem exposed to the 1-adrenoceptor 
agonist, phenylephrine, and a cocktail of drugs indica-
tive of a lack of glutamatergic and GABAergic tone on 
5-HT release from serotonergic neurons. These find-
ings strongly suggest that glutamatergic and GABAergic 
inputs to the DR do not contribute substantially to 5-HT 
cell autoinhibition. Moreover, the results are indicative 
of a relative scarcity of serotonergic transmission in the 
DR measured as the probability of evoking serotonergic 
inhibitory postsynaptic potentials (IPSC5-HT) in seroto-
nergic neurons. Most of the recorded neurons were lo-
cated in the dorsal and the ventromedial part of the DR, 
and higher IPSC5-HT success rates were reported in slices 
containing the centrocaudal extent of DR, which is the 
subdomain of the nucleus that projects to areas in the 
hippocampus that influence theta activity (Commons, 
2015), thought to underlie learning and memory.
Future prospects
Depression is the most common neuropsychiatric dis-
order and, according to World Health Organization, is 
predicted to be the second leading cause of global dis-
ability burden by 2020. Most existing antidepressant 
drugs target the serotonergic system but, unfortunately, 
they fall short of being adequate for a large subset of 
patients. One of the main drawbacks of such therapy is 
the therapeutic delay of SSRIs, for which the increase in 
extracellular 5-HT in the raphe nuclei is postulated to 
be a key factor. To overcome this problem, it is impor-
tant to characterize the precise mechanism(s) of trans-
mitter release in this structure. Previous work has shown 
that there are multiple ways to induce 5-HT release in 
raphe nuclei, as also observed in the forebrain (Adell 
et al., 1989). The study of Mlinar et al. (2015) uses an 
in vitro preparation to describe in detail a new mecha-
nism of nonexocytotic and nonvesicular release of 5-HT 
in the raphe nuclei. An important feature of this process 
is that it is not performed by reversal of SERT, which 
means that it cannot be inhibited by SSRIs. The in vitro 
nature of the study is a clear limitation and further re-
search is needed to determine its therapeutic potential. 
Should this nonexocytotic release of 5-HT in the raphe 
nuclei occur in vivo, it would represent an important 
target for antidepressant drugs inasmuch as raphe 5-HT 
exerts a fine tuning of the control of serotonergic trans-
mission throughout the brain.
Elizabeth M. Adler served as editor.
mechanisms that fill the extracellular compartment of 
the DR with 5-HT.
Mechanisms of 5-HT release in the raphe nuclei
SSRIs produce a sustained increase in extracellular 5-HT 
in the DR, and this leads to autoinhibition of serotoner-
gic neurons. However, it is clear that, even though the 
5-HT1A autoreceptors are activated by extracellular 5-HT, 
the transmitter must be released in some way (presum-
ably independent of 5-HT cell firing) to replenish the 
extracellular pool. Various mechanisms have been sug-
gested to explain the local release of 5-HT from DR 
neurons in the raphe nucleus. Several earlier studies sug-
gested that extracellular 5-HT in the raphe nuclei de-
pended on neuronal stimulation and release from storage 
vesicles by exocytosis (Matos et al., 1996; Portas et al., 
1996; Tao et al., 1997) (see Fig. 1). The thorough study 
by Mlinar et al. (2015) now shows for the first time that 
substantial nonexocytotic 5-HT release takes place in 
the absence of neuronal activity, Ca2+ influx, or vesicu-
lar monoamine transporter 2–mediated vesicular accu-
mulation of 5-HT. Furthermore, Mlinar et al. elegantly 
demonstrate that blockade of SERT by an SSRI does not 
disrupt nonexocytotic release of 5-HT, ruling out the 
possibility that it depends on reverse transport by SERT. 
Collectively, their results suggest that a prominent frac-
tion of extracellular 5-HT in the raphe nuclei is released 
from a cytoplasmic pool by simple diffusion across the 
Figure 1. Schematic drawing of a 5-HT neuron showing exocy-
totic release from vesicles (red arrow) and the nonexocytotic re-
lease described by Mlinar et al. (2015) (blue arrow). Reuptake of 
5-HT through SERT is depicted with a green arrow. SSRIs block 
SERT, thus inhibiting reuptake of 5-HT. Monoamine oxidase 
(MAO) enzyme is located in the external mitochondrial wall.
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